Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03687632
Previous Study | Return to List | Next Study

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03687632
Recruitment Status : Completed
First Posted : September 27, 2018
Last Update Posted : August 18, 2021
Sponsor:
Information provided by (Responsible Party):
Noveome Biotherapeutics, formerly Stemnion

Tracking Information
First Submitted Date  ICMJE September 24, 2018
First Posted Date  ICMJE September 27, 2018
Last Update Posted Date August 18, 2021
Actual Study Start Date  ICMJE June 10, 2019
Actual Primary Completion Date August 18, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 13, 2020)
Proportion of subjects with complete healing of PED during 28 days of treatment starting [ Time Frame: 28 days ]
Healing is defined as the complete re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
Original Primary Outcome Measures  ICMJE
 (submitted: September 25, 2018)
Percent of subjects with complete healing [ Time Frame: 28 days ]
Healing is defined as the complete re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 13, 2020)
  • Safety endpoint of the incidence of adverse and serious adverse events [ Time Frame: 28 days ]
    The secondary safety endpoint is the incidence of adverse and serious adverse events throughout the 28 days of treatment. For the safety evaluation, changes in visual acuity, IOP, and fluorescein staining will be considered as safety measures.
  • Percent of subjects with complete healing within 14 days of starting treatment [ Time Frame: 14 days ]
    Healing is defined as the complete re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
  • Time (in days) to complete re-epithelialization of the study eye [ Time Frame: This assessment will occur during clinic visits on days 4, 8, 11, 15, 22 and 29. ]
    Re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
  • Persistence of complete corneal re-epithelialization in the study eye [ Time Frame: The measurement will be made 7 days after end of treatment (at end of study visit). ]
    Corneal re-epithelialization in the study eye as determined by whether the healed epithelium remains intact after complete re-epithelialization is confirmed in the study eye, as determined by slit lamp examination with fluorescein staining.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 25, 2018)
  • Safety endpoint of the incidence of adverse and serious adverse events [ Time Frame: 28 days ]
    The secondary safety endpoint is the incidence of adverse and serious adverse events throughout the 28 days of treatment. For the safety evaluation, changes in visual acuity, IOP, and fluorescein staining will be considered as safety measures.
  • Percent of subjects with complete healing [ Time Frame: 14 days ]
    Healing is defined as the complete re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
  • Time (in days) to complete re-epithelialization of the study eye [ Time Frame: This assessment will occur during clinic visits on days 4, 8, 11, 15, 22 and 29. ]
    Re-epithelialization of the epithelial defect as determined by slit lamp examination with fluorescein staining.
  • Persistence of complete corneal re-epithelialization in the study eye [ Time Frame: The measurement will be made 7 days after end of treatment (at end of study visit). ]
    Corneal re-epithelialization in the study eye as determined by whether the healed epithelium remains intact after complete re-epithelialization is confirmed in the study eye, as determined by slit lamp examination with fluorescein staining.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Official Title  ICMJE A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Brief Summary The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
Detailed Description

Efficacy:

The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment. Failures are subjects that do not completely heal during 28 days of therapy. The epithelial defect can be of any size as long as it is measurable by slit lamp. The longest measurement and the measurement perpendicular to that will be determined and the area calculated. The change in area and perimeter of epithelial defect from baseline through Day 15 (14 days of treatment) and Day 29 (28 days of treatment) will be calculated for each subject. The time to complete re-epithelialization is defined as the time from the start of therapy (Baseline Visit/Day 1) to the Day when no defect is observed. The number and percent of responders and failures will be summarized at each visit. Graphical representation of percent of responders and failures will be provided. The change in area and perimeter of epithelial defect from baseline through Day 15 (14 days of treatment) and Day 29 (28 days of treatment) will be summarized. Visualization of mean (Standard Deviation) of the change in area and perimeter will be provided at each time point. The time to complete re-epithelialization will be summarized and listed.

Safety:

Subject demographics, baseline characteristics and relevant medical history will be summarized and listed. Data for ST266 administration and concomitant therapies will be listed.

The number and percent of subjects with treatment emergent adverse events and ST266 related adverse events will be tabulated by system organ class and preferred terms.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
This is a Phase 2, open label trial to determine if treatment with ST266 eye drops for 28 days heals the study eye.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Persistent Corneal Epithelial Defect
Intervention  ICMJE Biological: ST266
1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
Study Arms  ICMJE Experimental: Single arm - active
ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
Intervention: Biological: ST266
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 22, 2020)
13
Original Estimated Enrollment  ICMJE
 (submitted: September 25, 2018)
20
Actual Study Completion Date  ICMJE August 25, 2020
Actual Primary Completion Date August 18, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female subjects aged 18 years and over.
  • Subjects with a PED present for at least seven (7) days.
  • The defect may be of any size and must be measurable by slit lamp.
  • In the Investigator's opinion, the defect is persistent i.e., the defect has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
  • The original defect to the cornea must be the result of any injury, infection, disease or surgery to the eye.

Exclusion Criteria:

  • Subjects currently being treated with cenegermin.
  • Subjects who require treatment with autologous serum eyedrops throughout the duration of the trial. If, in the opinion of the investigator, autologous serum eyedrop treatment can be safely stopped, the subject may be included in the clinical trial.
  • Subjects who require treatment with other amnion products throughout the duration of the trial. If, in the opinion of the investigator, the amniotic product treatment can be safely stopped, the subject may be included in the clinical trial.
  • Subject who requires treatment with amniotic membrane throughout the duration of the trial. If the amniotic membrane can be safely stopped, the subject may be included in the clinical trial. Note: The amniotic membrane must be removed at least one (1) day prior to the baseline visit.
  • Subjects who require treatment with bandage contact lens that cannot be removed at least 24 hours prior to screening. If the bandage contact lens can be safely removed, the subject may be included in the clinical trial.
  • Subject with an uncontrolled lid or ocular infection.
  • History of alkali burns of the cornea.
  • The circumference affected by limbal blood vessel ischemia is greater than 75 percent of the circumference.
  • Subjects with severe lid abnormalities contributory to the persistence of the PED such as the inability to close the lids.
  • Subjects who have a history of AIDS or HIV.
  • Treatment with systemic corticosteroids (equivalent to >10 mg/day of prednisone) or immunosuppressive (including Plaquenil) or chemotherapeutic agents within 7 days prior to Day 1, or likely to receive one of these therapies during study participation.
  • Subjects who have participated in a clinical trial within 30 days prior to Day 1.
  • Subjects who have more than one distinct PED in the study eye prior to screening visits. Subjects who develop PEDs after the screening visit will remain in the study; however, only the original study PED will be assessed.
  • Subjects with bullous keratopathy.
  • Subjects with corneal perforation or impending corneal perforation.
  • For subjects with bilateral PEDs, only the eye with the larger PED should be entered in to the study. The non-study eye will receive standard of care treatment and will be observed throughout the trial.
  • Female subjects who are pregnant or breastfeeding. Female subjects who are neither postmenopausal nor surgically sterile require a negative urine pregnancy test on Day 1 visit.
  • Epithelial defect was classified as a progressive corneal melt caused by an immunological process such as rheumatoid melt or Mooren's ulceration.
  • Subjects with recurrent corneal erosion.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03687632
Other Study ID Numbers  ICMJE ST266-PED-201
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Noveome Biotherapeutics, formerly Stemnion
Study Sponsor  ICMJE Noveome Biotherapeutics, formerly Stemnion
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Noveome Biotherapeutics, formerly Stemnion
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP